ClinicalTrials.gg
TerminatedNCT06502990Updated Jul 22, 2026

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

A Phase 3 interventional study of Metreleptin in Generalized Lipodystrophy, sponsored by Amryt Pharma. Terminated at 12 sites in 4 countries. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Amryt Pharma (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
This clinical trial was closed early due to no longer being a requirement to the European Medicines Agency.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
Up to 5 Years
Sex
All
01

Study summary

This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia

02

Conditions studied

  • Generalized Lipodystrophy

Keywords

  • Metreleptin
03

In context

Lead sponsor

Amryt Pharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted after Amryt Pharma became part of Chiesi Farmaceutici S.p.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Generalised Lipodystrophy
  • Metreleptin treatment naive

Exclusion criteria

Exclusion Criteria:

  • Weight \<9 kg at Screening (Visit 1)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Metreleptin

    Metreleptin \[Recombinant-methionyl human Leptin; rmetHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake

    Drug: Metreleptin

Interventions

  • Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in fasting serum TG levels at Month 12 for subjects with fasting TG levels ≥2.3 mmol/L (200 mg/dL) at baseline

    To evaluate the effectiveness of metreleptin in patients under 6 years of age with GL and associated diabetes mellitus and/or hypertriglyceridaemia

    Time frame: 12 months

  2. Absolute change from baseline in glycated haemoglobin (HbA1c) at Month 12 for subjects with HbA1c ≥6.5% at baseline

    To evaluate the effectiveness of metreleptin in patients under 6 years of age with GL and associated diabetes mellitus and/or hypertriglyceridaemia

    Time frame: 12 months

Secondary outcomes

  1. Proportion of subjects of those with Baseline HbA1c ≥6.5% achieving target actual decreases of at least 0.5%, 1%, 1.5%, 2% absolute decrease in HbA1c or HbA1c <6.5% or HbA1c <5.7% at Month 12

    To evaluate the efficacy of metreleptin treatment in patients with GL

    Time frame: 12 months

  2. Proportion of subjects of those with Baseline HbA1c ≥5.7% achieving target actual decreases of at least 0.5%, 1%, 1.5%, 2% absolute decrease in HbA1c or HbA1c <5.7% at Month 12

    To evaluate the efficacy of metreleptin treatment in patients with GL

    Time frame: 12 months

  3. Proportion of subjects of those with fasting serum TG ≥ 1.7 mmol/L (150 mg/dL) achieving target actual decreases from baseline of at least 15%, 20%, 25%, 30%, 35%, 40% at Month 12

    To evaluate the efficacy of metreleptin treatment in patients with GL

    Time frame: 12 months

  4. Proportion of subjects of those with fasting serum TG ≥ 2.3 mmol/L (200 mg/dL) achieving target actual decreases from baseline of at least 15%, 20%, 25%, 30%, 35%, 40% at Month 12

    To evaluate the efficacy of metreleptin treatment in patients with GL

    Time frame: 12 months

  5. Change from baseline in liver volume and liver span as assessed by ultrasound at each post-baseline visit through Month 12

    To evaluate the efficacy of metreleptin treatment in patients with GL

    Time frame: 12 months

  6. Incidence of, treatment emergent adverse events (TEAEs), serious adverse events (SAEs), treatment related adverse events (AEs), AEs of special interest (AESIs) and AEs leading to study drug discontinuation

    To assess safety and tolerability of metreleptin

    Time frame: 12 months

07

Study locations

12 sites
  • UZ Leuven
    Leuven, Leuven 3000, Belgium
  • Hôpital Necker - Enfants Malades
    Paris, Paris 75015, France
  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Universitaire Robert-Debre
    Paris, France
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Free and Hanseatic City of Hamburg 20251, Germany
  • Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin
    Ulm, Ulm 89075, Germany
  • IRCCS Ospedale Pediatrico Bambino Gesù
    Chieti, Chieti 66100, Italy
  • Azienda Ospedaliera Universitaria "Federico II"
    Naples, Naples 80131, Italy
  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
    Novara, Novara 28100, Italy
  • Azienda Ospedaliero-Universitaria di Parma
    Parma, Parma 43126, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Pisa 56124, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesù
    Rome, Rome 00165, Italy
  • Ospedale Filippo Del Ponte Varese - ASST Sette Laghi
    Varese, Varese 21100, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Feb 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 16, 2024
StartActual
May 23, 2025
Primary completionActual
Feb 11, 2026
CompletionActual
Feb 11, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06502990
Lead sponsor
Amryt Pharma
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
May 23, 2025
Primary completion
Feb 11, 2026
Completion
Feb 11, 2026
Last update
Jul 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metreleptin

Start the discussion